Outcome analysis of alternative donor allogeneic hematopoietic cell transplantation in the treatment of 19 severe aplastic anemia patients.
- VernacularTitle:替代供者异基因造血干细胞移植治疗重型再生障碍性贫血19例疗效分析
- Author:
Xin CHEN
1
;
Jialin WEI
1
;
Yong HUANG
1
;
Yi HE
1
;
Donglin YANG
1
;
Erlie JIANG
1
;
Qiaoling MA
1
;
Jianfeng YAO
1
;
Lukun ZHOU
1
;
Xiaoting LIN
1
;
Yuyan SHEN
1
;
Xin YANG
1
;
Zhao WANG
1
;
Sizhou FENG
1
;
Mingzhe HAN
1
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Anemia, Aplastic; therapy; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Retrospective Studies; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2014;35(1):9-12
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of alternative donor allogeneic hematopoietic stem cell transplantation (AD allo-HSCT) in the treatment of severe aplastic anemia (SAA).
METHODSRetrospective analysis of the clinical data of 19 SAA patients received AD allo-HSCT from May 2003 to December 2012. Of them, 12 received haploidentical HSCT (haplo-HSCT), 7 received unrelated donor transplantation. The conditioning regimen was CY+ATG+Flu±Ara-C±Bu/Mel, the GVHD preventing regimen was MMF+MTX+CSA/FK506; the median reinfusion quantity of CD34+ was 3.10(2.11-4.38)×10⁶/kg in allo-BMT and 4.90(2.08-6.88)×10⁶/kg in allo-PBSCT.
RESULTSHematopoiesis reconstitution was achieved in all 19 patients. Twelve patients developed acute graft-versus-host disease (aGVHD), and 7 developed chronic GVHD (cGVHD). Graft rejection (GR) was occurred in one patient. The median follow-up time was 13(3-115) months. Thirteen patients survived, and the prospective 5-year overall survival rate is (67.5±11.0)%.
CONCLUSIONAD allo-HSCT can be used as an alternative therapy for SAA patients without HLA matched sibling donor.
